Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Inv. presentation
Employment agrmnt
Director departure
Appointed director
|
|
UNIGENE LABORATORIES INC (UGNE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/12/2013 |
8-K
| Quarterly results|
Docs:
|
"UNIGENE LABORATORIES, INC. BALANCE SHEETS DECEMBER 31, 2012 and 2011 2012 2011 ASSETS Current Assets: Cash and cash equivalents $ 3,813,492 $ 4,681,683 Accounts receivable 76,255 2,854,038 Accounts receivable - Tarsa -- 8,193 Inventory, net 898,042 1,283,550 Due from former China joint venture partner -- 600,000 Prepaid expenses and other current assets 848,573 862,761 Total Current Assets 5,636,362 10,290,225 Noncurrent inventory, net 1,063,633 1,946,647 Property, plant and equipment, net 2,651,819 2,977,058 Patents and other intangibles, net 1,920,574 2,020,458 Deferred financing costs, net -- 619,767 Other assets 40,513 341,014 Total Assets $ 11,312,901 $ 18,195,169 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable $ 731,359 $ 1,472,925 Accrued expenses 2,244,8..." |
|
| 08/09/2012 |
8-K
| Quarterly results |
| 03/08/2012 |
8-K
| Quarterly results |
| 05/09/2011 |
8-K
| Quarterly results |
| 03/10/2011 |
8-K
| Quarterly results|
Docs:
|
"Unigene Reports Fourth Quarter and Full Year 2010 Financial Results -Company anticipates cash runway extension into 2H 2012 and multiple potential milestones- -Company expects 2011 will be transformational- March 10, 2011 –BOONTON, N.J. -- -- Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced fourth quarter and full year financial results for the period ended December 31, 2010. The Company also identified multiple key milestones anticipated in 2011. Fourth Quarter and Full-Year 2010 Financial Summary Unigene announced net loss of $0.04 per share for the three months ended December 31, 2010. For the year ended December 31, 2010, the net loss was $.30 per share. Cash at December 31, 2010 was $12.2 million, an incre..." |
|
| 08/09/2010 |
8-K
| Quarterly results|
Docs:
|
"Unigene Announces Financial Results For Second Quarter 2010 BOONTON, N.J. – August 9, 2010 -- Unigene Laboratories, Inc. has reported its financial results for the quarter ended June 30, 2010. Revenue for the three months ended June 30, 2010 was $3,028,000, compared to $4,297,000 for the three months ended June 30, 2009. Revenue for both periods primarily consisted of Fortical sales and royalties which have declined since the launch of competitive products in December 2008. Fortical sales were $1,387,000 for the three months ended June 30, 2010, compared to $2,730,000 for the three months ended June 30, 2009. Fortical sales fluctuate each quarter based upon Upsher-Smith Laboratories' ordering schedule. Fortical royalties were $906,000 for the three months ended June 30, 2010, compared to $..." |
|
| 03/16/2010 |
8-K
| Quarterly results|
Docs:
|
"Unigene Reports Financial Results for Fourth Quarter And Year-End 2009 BOONTON, N.J. - March 16, 2010 - Unigene Laboratories, Inc. has reported its financial results for the quarter and year ended December 31, 2009. Revenue for the three months ended December 31, 2009 was $2,572,000, compared to $4,854,000 for the three months ended December 31, 2008, and $12,792,000 for the year ended December 31, 2009, compared to $19,229,000 for the year ended December 31, 2008. Revenue for all periods primarily consisted of Fortical sales and royalties, which were $10,932,000 for the year ended December 31, 2009, and $16,578,000 for the year ended December 31, 2008. Fortical royalties were $4,991,000 for the year ended December 31, 2009, compared to $6,520,000 for the year ended December 31, 2008. Fort..." |
|
| 11/09/2009 |
8-K
| Form 8-K - Current report |
| 08/10/2009 |
8-K
| Quarterly results|
Docs:
|
"Unigene Announces Financial Results For Second Quarter 2009 BOONTON, N.J. — August 10, 2009 — Unigene Laboratories, Inc. has reported its financial results for the quarter ended June 30, 2009. Revenue for the three months ended June 30, 2009 was $4,297,000, compared to $4,978,000 for the three months ended June 30, 2008. Revenue for both periods primarily consisted of Fortical sales and royalties, which were $3,807,000 for the three months ended June 30, 2009, and $4,110,000 for the three months ended June 30, 2008. Fortical royalties were $1,077,000 for the three months ended June 30, 2009, compared to $1,475,000 for the three months ended June 30, 2008. Fortical sales were $2,730,000 for the three months ended June 30, 2009, compared to $2,635,000 for the three months ended June 30, 2008..." |
|
| 11/09/2006 |
8-K
| Quarterly results|
Docs:
|
"Unigene Announces Results for the Third Quarter of 2006 FAIRFIELD, N.J. - November 9, 2006 — Unigene Laboratories, Inc. announced its financial results for September 30, 2006. Revenue for the three months ended September 30, 2006 was $1,701,000 compared to $11,873,000 for the three months ended September 30, 2005 and $2,644,000 for the nine months ended September 30, 2006 compared to $12,676,000 for the nine months ended September 30, 2005. Revenue from Fortical sales and royalties were $1,510,000 for the three months ended September 30, 2006, $348,000 for the three months ended June 30, 2006 and $197,000 for the three months ended March 31, 2006. Fortical royalties were $673,000 and $2,007,000 respectively, for the three months ended September 30, 2006 and 2005 and $1,218,000 and $2,007,0..." |
|
| 08/10/2006 |
8-K
| Quarterly results|
Docs:
|
"Unigene Announces Results for the Second Quarter of 2006 FAIRFIELD, N.J. - August 10, 2006 — Unigene Laboratories, Inc. announced its financial results for June 30, 2006. Revenue for the three months ended June 30, 2006 was $556,000 compared to $215,000 for the three months ended June 30, 2005 and $943,000 for the six months ended June 30, 2006 compared to $803,000 for the six months ended June 30, 2005. Fortical royalties were $348,000 for the three months ended June 30, 2006 and $546,000 for the six months ended June 30, 2006. Our net loss for the three months ended June 30, 2006 was $3,002,000, or $.03 per share, compared to a net loss of $2,486,000, or $.03 per share, for the three months ended June 30, 2005. The three months ended June 30, 2006 includes $271,000 in expenses for non-ca..." |
|
| 05/11/2006 |
8-K
| Quarterly results|
Docs:
|
"Unigene Announces Results for the First Quarter of 2006 FAIRFIELD, N.J. - May 11, 2006 — Unigene Laboratories, Inc. announced its financial results for the quarter ended March 31, 2006. Revenue for the quarter ended March 31, 2006 was $387,000 compared to $588,000 for the quarter ended March 31, 2005. Unigene's net loss for the quarter ended March 31, 2006 was $3,243,000 or per share compared to a net loss of $3,254,000 or per share for the quarter ended March 31, 2005. The quarter ended March 31, 2006 includes $178,000 in non-cash stock option compensation expense resulting from the adoption of SFAS 123 . Our cash balance at March 31, 2006 was $11,200,000, an increase of $7,000,000 from year-end. This was primarily a result of our private placement in March. The reduction in short-term de..." |
|
|
|